Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
Gold nanoparticles that cluster in response to T cell enzymes can predict cancer immunotherapy success days before tumors ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
One of the most striking breakthroughs of Belarusian medicine in the field of oncology is CAR‑T‑cell therapy. 85 people have already ...
BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 Pharmaceutical Technology Excellence Awards.
Human immunodeficiency virus (HIV) infections are still fairly common and an estimated 40 million people worldwide are ...
Researchers have shown that glioblastoma can take over the skull marrow to dissolve bone and feed its own growth, suggesting a systemic, not localized, illness.
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...
Salk scientists discovered the protein CCN1—secreted by non-neuronal brain cells called astrocytes—stabilizes brain circuits in adulthood. The CCN1 pathway may be a powerful target for therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback